

The Drugs and Therapeutics Committee

Friday, 9^h, February, 2017: 12.30-2.30 PM
Lydeard House, Meeting Room 1, MPH

Please bring along any refreshments that you may require to the meeting.

AGENDA

1 Welcome

2 Apologies for absence

3 Declaration of interests

4 Minutes of last DTC meeting

5 Minutes of APG meetings

6 Matters arising

- 6.1 Opicapone – outcomes to be reported at May meeting.(CB)
- 6.2 Lidocaine patches guideline and implementation (CB)
- 6.3 GCSF policy (CB)
- 6.4 SOP (Pharmacy): Enabling protocol for pharmacists.(MA)
- 6.5 Ecolab chlorhexidine 2% in 70% alcohol (JB)
- 6.6 Low value medicines. (JB)
- 6.7 Magnesium sulphate injection 50% (Susan Mason, Senior Midwife)

7 Applications completed by virtual D&TC process

- 7.1 Unlicensed Drugs Policy (review, no changes). Approved: 10/03/2017..
- 7.2 Guideline lidocaine patches (following guideline clarification). Approved: 29/12/2017
- 7.3 Controlled Drugs (CD) Policy reviewed. Accepted (no changes): 29/12/2017.
- 7.4 Drugs Policy reviewed. Accepted (minor changes): 8/1/2018.
- 7.5 Hyoscine-N-butylbromide (Buscopan™) inj. shortage (glycopyrronium switch) for palliative care 4/2/2018.

8 Progress of TAs implementation, report from Lincoln Andrews.

9 Nutritional products Ursula Green, Lead for nutrition and dietetics.

10 CDF Drugs (CB)

11 Early Access to Medicines Scheme (EAMS)

- 11.1 Early access to medicines scheme (EAMS): Nivolumab to treat advanced or recurrent gastric or gastroesophageal junction cancer after two or more systemic therapies.
- 11.2 Early access to medicines scheme (EAMS): Emicizumab for routine prophylaxis of bleeding episodes in patients, aged 1 year and over, with haemophilia A with factor VIII inhibitors

12 Regional Medicines Optimisation Committees (RMOCs) (NA)

- 12.1 First Wave RMOCS discussions: AMR, biosimilars, polypharmacy.
- 12.2 Position statements: Free Style Libra.
- 12.3 New workload topics submitted to RMOCS including: homely remedies, low clinical value medicines, shared care and compassionate care / FOC medicines guidance

13 IV Immunglobulins

- 13.1 IAPs – best practice.
- 13.2 1 **GREY** Q1 to date: Melanoma associated retinopathy IFR required.
- 13.3 13 **BLUE** Q1 to date: Staph / Strep TSS (2), CIDP (4), Myasthenia gravis (3), Multifocal motor neuropathy (1), Secondary antibody deficiencies (1), Chronic lymphocytic leukaemia (1), Dermatomyositis (1). In each episode the Consultant has confirmed that the patient met the criteria for Immunoglobulin treatment for the diagnosis as outlined in the guidelines for Immunoglobulin use:
- 13.4 Database completion. Q2 2017-18.

14 NICE TAs

NICE TA	Name	Recommendation
487	Venetoclax for treating chronic lymphocytic leukaemia	Recommended
488	Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours	Recommended
489	Vismodegib for treating basal cell carcinoma	Not recommended
490	Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy	Recommended
491	Ibrutinib for treating Waldenstrom's macroglobulinaemia	Recommended
492	Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable	Recommended
493	Cladribine tablets for treating relapsing–remitting multiple sclerosis	Recommended
494	Naltrexone–bupropion for managing overweight and obesity	Not recommended
495	Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer	Recommended
496	Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer	Recommended
497	Golimumab for treating non-radiographic axial spondyloarthritis	Recommended
498	Lenvatinib with everolimus for previously treated advanced renal cell carcinoma	Recommended
499	Glecaprevir–pibrentasvir for treating chronic hepatitis C	Recommended
500	Ceritinib for untreated ALK-positive non-small-cell lung cancer	Recommended
501	Intrabeam radiotherapy system for adjuvant treatment of early breast cancer	Not recommended
502	Ibrutinib for treating relapsed or refractory mantle cell lymphoma	Recommended
503	Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer	Not recommended

13 New Drug Requests

- 13.1 Methoxyflurane inhalation vapour (Penthrox™) for emergency pain relief in trauma patients.
- 13.2 Palonestron / netipitant (Akynzeo™) for the prevention of acute and delayed N&V associated with emetogenic chemotherapy

14 MHRA Drug Safety Updates – circulation to CSLs: 11/2017, 12/2017, 1/2018 and 2/2018.

15 Other Formulary issues

- 15.1 Trelegy™ Ellipta.
- 15.2 Delmosart™ (methylphenidate) prolonged release.
- 15.3 Desitrend™ (levetiracetam) granules.

16 Shared care protocols

- 16.1 Disease Modifying Anti-Rheumatic Drugs (DMARDS)

17 Any other Business

18 Next meeting dates: 11th May, 27th July, 23rd November.